GoldenGolden
Advanced Search
ViThera Pharmaceuticals

ViThera Pharmaceuticals

A pharmaceutical company that combines probiotics with synthetic biology to create novel therapeutics for chronic diseases. The underlying concept of their strategies is to used genetically engineered probiotic bacteria as vectors for the delivery of therapeutic proteins for the treatment of inflammatory bowel disease.

All edits

Edits on 11 May, 2021
Golden AI"Funding autocalculation"
Golden AI edited on 11 May, 2021
Edits made to:
Infobox (+2 properties)
Infobox
Latest funding round date
November 2010
Latest funding type
Grant (money)
Edits on 30 Apr, 2021
Rahul Goyal
Rahul Goyal edited on 30 Apr, 2021
Edits made to:
Infobox (+4 properties)
Infobox
Edits on 20 Apr, 2021
Golden AI"Found on funding round"
Golden AI edited on 20 Apr, 2021
Edits made to:
Infobox (+1 properties)
Infobox
Investors
Golden AI
Golden AI edited on 20 Apr, 2021
Edits made to:
Infobox (+1 properties)
Chirag Jain
Chirag Jain edited on 20 Apr, 2021
Edits made to:
Infobox (+1 properties)
Edits on 22 Mar, 2021
Golden AI
Golden AI edited on 22 Mar, 2021
Edits made to:
Infobox (+1 properties)
Infobox
Golden AI
Golden AI edited on 22 Mar, 2021
Edits made to:
Infobox (+1 properties)
Infobox
Bhupendra Solanki
Bhupendra Solanki edited on 22 Mar, 2021
Edits made to:
Infobox (--2 properties)
Infobox
Company status
Active
Number of Employees (ranges)
5 – 9
Edits on 27 Feb, 2021
Neelam Jhaveri
Neelam Jhaveri approved a suggestion from Golden's AI on 27 Feb, 2021
Edits made to:
Article (+17/-17 characters)
Article

Johannes Fruehauf, Founder of ViThera was previously employed by Cequent Pharmaceuticals. Cequent merged with MDRNA and the combined firm was renamed Marina Biotech. ViThera employed some former researchers from the company Cequent, which developed engineered E. Coli bacteria for the delivery of RNA-interference (RNAi) drugs to the gut called transkingdom RNAi (tkRNAi). ViThera conducted contract research to partially fund its own projects and served clients focused on RNAi, and that side of the business has been renamed Cambridge BiolabsCambridge Biolabs. Cambridge Biolabs maintains a license to tkRNAi and Marina Biotech is eligible for milestone and royalty payments from those programs. Cambridge Biolabs continues to provide custom laboratory services and is independent from ViThera.

Edits on 23 Feb, 2021
Golden AI"Setting founded date to the company's date of incorporation."
Golden AI edited on 23 Feb, 2021
Edits made to:
Infobox (+1 properties)
Infobox
Founded date
2009
Edits on 1 May, 2020
Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI on 1 May, 2020
Edits made to:
Article (+17/-17 characters)
Article

ViThera has partnered with Johnson & JohnsonJohnson & Johnson.

Neelam Jhaveri
Neelam Jhaveri approved a suggestion from Golden's AI on 1 May, 2020
Edits made to:
Article (+14/-14 characters)
Article

Johannes Fruehauf, Founder of ViThera was previously employed by Cequent Pharmaceuticals. Cequent merged with MDRNA and the combined firm was renamed Marina BiotechMarina Biotech. ViThera employed some former researchers from the company Cequent, which developed engineered E. Coli bacteria for the delivery of RNA-interference (RNAi) drugs to the gut called transkingdom RNAi (tkRNAi). ViThera conducted contract research to partially fund its own projects and served clients focused on RNAi, and that side of the business has been renamed Cambridge Biolabs. Cambridge Biolabs maintains a license to tkRNAi and Marina Biotech is eligible for milestone and royalty payments from those programs. Cambridge Biolabs continues to provide custom laboratory services and is independent from ViThera.

Nico Faraguna
Nico Faraguna edited on 30 Apr, 2020
Edits made to:
Infobox (--1 properties)
Infobox
Edits on 13 Sep, 2019
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 13 Sep, 2019
Edits made to:
Article (+27/-27 characters)
Article

ViThera’s research combines probiotics with synthetic biology to create novel therapeutics for chronic diseases. The company’s strategies use the concept of using genetically engineered probiotic bacteria as vectors for the delivery of therapeutic proteins that target the intestinal epithelium for treatment of inflammatory bowel diseasesinflammatory bowel diseases like Crohn's disease and ulcerative colitis.

Edits on 13 Sep, 2019
Julius John Villarisco
Julius John Villarisco approved a suggestion from Golden's AI on 13 Sep, 2019
Edits made to:
Article (+23/-23 characters)
Article

Johannes Fruehauf, Founder of ViThera was previously employed by Cequent PharmaceuticalsCequent Pharmaceuticals. Cequent merged with MDRNA and the combined firm was renamed Marina Biotech. ViThera employed some former researchers from the company Cequent, which developed engineered E. Coli bacteria for the delivery of RNA-interference (RNAi) drugs to the gut called transkingdom RNAi (tkRNAi). ViThera conducted contract research to partially fund its own projects and served clients focused on RNAi, and that side of the business has been renamed Cambridge Biolabs. Cambridge Biolabs maintains a license to tkRNAi and Marina Biotech is eligible for milestone and royalty payments from those programs. Cambridge Biolabs continues to provide custom laboratory services and is independent from ViThera.

Meredith Hanel
Meredith Hanel edited on 13 Sep, 2019
Edits made to:
Topic thumbnail

ViThera Pharmaceuticals

A pharmaceutical company that combines probiotics with synthetic biology to create novel therapeutics for chronic diseases. The underlying concept of their strategies is to used genetically engineered probiotic bacteria as vectors for the delivery of therapeutic proteins for the treatment of inflammatory bowel disease.

Meredith Hanel
Meredith Hanel edited on 13 Sep, 2019
Edits made to:
Infobox (+1 properties)
Description (+320 characters)
Article (+1880 characters)
Table (+8 rows) (+16 cells) (+263 characters)
Categories (+3 topics)
Related Topics (+3 topics)
Topic thumbnail

ViThera Pharmaceuticals

A pharmaceutical company that combines probiotics with synthetic biology to create novel therapeutics for chronic diseases. The underlying concept of their strategies is to used genetically engineered probiotic bacteria as vectors for the delivery of therapeutic proteins for the treatment of inflammatory bowel disease.

Article

ViThera’s research combines probiotics with synthetic biology to create novel therapeutics for chronic diseases. The company’s strategies use the concept of using genetically engineered probiotic bacteria as vectors for the delivery of therapeutic proteins that target the intestinal epithelium for treatment of inflammatory bowel diseases like Crohn's disease and ulcerative colitis.

History

Johannes Fruehauf, Founder of ViThera was previously employed by Cequent Pharmaceuticals. Cequent merged with MDRNA and the combined firm was renamed Marina Biotech. ViThera employed some former researchers from the company Cequent, which developed engineered E. Coli bacteria for the delivery of RNA-interference (RNAi) drugs to the gut called transkingdom RNAi (tkRNAi). ViThera conducted contract research to partially fund its own projects and served clients focused on RNAi, and that side of the business has been renamed Cambridge Biolabs. Cambridge Biolabs maintains a license to tkRNAi and Marina Biotech is eligible for milestone and royalty payments from those programs. Cambridge Biolabs continues to provide custom laboratory services and is independent from ViThera.

Products

Dr. Johannes Fruehauf and the ViThera team brought the first bacteria-based RNAi drug delivery platform to clinical trials.

EnLact (ENhanced Lactococcus) strains are engineered lactic acid bacteria and probiotic bacteria that express beneficial proteins and modulate disease within the patient’s body. ViThera’s lead program, VT301, uses EnLact technology and is for the treatment of Inflammatory Bowel Disease. VT301 is claimed to heal the epithelial lining of the gut without affecting the immune system. The EnLact® strains in VT301 express human anti-inflammatory proteins that act locally on the inflamed mucosa and avoid systemic side effects.

ViThera has partnered with Johnson & Johnson.

Table

Name
Role
LinkedIn

Bernard Malfroy-Camine (PhD)

President, CEO

Grazyna Szymanska-Schellenberg

VP Corporate Development

Johannes Fruehauf MD PhD

Founder and CSO

Lisa Velardo

CFO

Pamela Fekete MD, JD, MS

Director

Peter D. Parker

Advisor

Philippe Langella

Co-Founder

R. Balfour Sartor, MD

Head of SAB

Infobox
Date incorporated
2009
Categories
Related Topics
Edits on 9 Sep, 2019
Dawson Sewell
Dawson Sewell edited on 9 Sep, 2019
Edits made to:
Infobox (+4 properties)
Dawson Sewell"Initial topic creation"
Dawson Sewell created this topic on 9 Sep, 2019
Edits made to:
Topic thumbnail

 ViThera Pharmaceuticals

A pharmaceutical company that combines probiotics with synthetic biology to create novel therapeutics for chronic diseases. The underlying concept of their strategies is to used genetically engineered probiotic bacteria as vectors for the delivery of therapeutic proteins for the treatment of inflammatory bowel disease.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.